209 related articles for article (PubMed ID: 39307)
1. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia.
Gunne LM; Bárány S
Psychopharmacology (Berl); 1979 Jun; 63(3):195-8. PubMed ID: 39307
[TBL] [Abstract][Full Text] [Related]
2. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Domino EF
Psychopharmacology Suppl; 1985; 2():217-23. PubMed ID: 2860660
[TBL] [Abstract][Full Text] [Related]
3. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
4. Haloperidol-induced tardive dyskinesia in monkeys.
Gunne LM; Bárány S
Psychopharmacology (Berl); 1976 Nov; 50(3):237-40. PubMed ID: 826968
[TBL] [Abstract][Full Text] [Related]
5. Clozapine in tardive dyskinesia: observations from human and animal model studies.
Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
[TBL] [Abstract][Full Text] [Related]
6. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.
Gunne LM; Häggström JE; Sjöquist B
Nature; 1984 May 24-30; 309(5966):347-9. PubMed ID: 6727989
[TBL] [Abstract][Full Text] [Related]
7. Effects of sulpiride on persistent neuroleptic-induced dyskinesia in monkeys.
Häggström JE
Acta Psychiatr Scand Suppl; 1984; 311():103-8. PubMed ID: 6142586
[TBL] [Abstract][Full Text] [Related]
8. Development of acute dystonia and tardive dyskinesia in cebus monkeys.
Bárány S; Ingvast A; Gunne LM
Res Commun Chem Pathol Pharmacol; 1979 Aug; 25(2):269-79. PubMed ID: 115074
[TBL] [Abstract][Full Text] [Related]
9. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
10. Fluphenazine-induced acute and tardive dyskinesias in monkeys.
Kovacic B; Domino EF
Psychopharmacology (Berl); 1984; 84(3):310-4. PubMed ID: 6440175
[TBL] [Abstract][Full Text] [Related]
11. Tardive dyskinesia: pathophysiology and animal models.
Casey DE
J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
[TBL] [Abstract][Full Text] [Related]
12. Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia.
Kovacic B; Ruffing D; Stanley M
J Neural Transm; 1986; 65(1):39-49. PubMed ID: 2870130
[TBL] [Abstract][Full Text] [Related]
13. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.
Lévesque C; Hernandez G; Mahmoudi S; Calon F; Gasparini F; Gomez-Mancilla B; Blanchet PJ; Lévesque D
Neuroscience; 2017 Oct; 361():43-57. PubMed ID: 28790021
[TBL] [Abstract][Full Text] [Related]
14. Application of a primate model for tardive dyskinesia.
Bárány S; Häggström JE; Gunne LM
Acta Pharmacol Toxicol (Copenh); 1983 Feb; 52(2):86-9. PubMed ID: 6846025
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects.
Liebman J; Neale R
Psychopharmacology (Berl); 1980; 68(1):25-9. PubMed ID: 6104837
[TBL] [Abstract][Full Text] [Related]
16. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
17. Neuroleptic-induced acute dyskinesias in rhesus monkeys.
Porsolt RD; Jalfre M
Psychopharmacology (Berl); 1981; 75(1):16-21. PubMed ID: 6117919
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
Linn GS; Lifshitz K; O'Keeffe RT; Lee K; Camp-Lifshitz J
Psychopharmacology (Berl); 2001 Jan; 153(3):285-94. PubMed ID: 11271400
[TBL] [Abstract][Full Text] [Related]
19. Experimental tardive dyskinesia.
Gunne LM; Häggström JE
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):48-50. PubMed ID: 2858481
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
